Published in BMC Infect Dis on September 17, 2015
An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis (2016) 0.82
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis (2016) 0.82
Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiol Infect (2016) 0.80
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis (2016) 0.77
Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis (2015) 0.76
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J Vaccines Vaccin (2016) 0.75
Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry. Front Immunol (2017) 0.75
Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol (2006) 3.86
Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood (2008) 3.44
Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA (2004) 2.60
Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect (2011) 2.28
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol (1998) 2.24
Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis (1997) 2.16
Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol (2007) 2.03
Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol (2000) 2.00
Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA (1996) 1.93
The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol (2009) 1.81
Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis (2003) 1.79
Vaccine-derived polioviruses. J Infect Dis (2014) 1.68
Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine (2009) 1.66
Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology (1999) 1.59
Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med (2011) 1.54
"A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol (2011) 1.49
Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res (2011) 1.40
Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol (2012) 1.36
Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc (2009) 1.30
Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep (2011) 1.29
Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ (2004) 1.28
Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill (2013) 1.23
Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ (1994) 1.20
Expert review on poliovirus immunity and transmission. Risk Anal (2012) 1.18
Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. J Clin Immunol (1988) 1.17
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal (2013) 1.16
Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals (2006) 1.11
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal (2006) 1.10
Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis (2014) 1.10
Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis (1997) 1.09
Transmission of wild poliovirus type 2--apparent global interruption. Wkly Epidemiol Rec (2001) 1.08
Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.07
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines (2012) 1.06
Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol (1981) 1.06
Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill (2010) 1.05
Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal (2013) 1.05
Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative. PLoS Pathog (2015) 1.05
Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis (2014) 1.03
Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis (2014) 0.99
An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96
High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol (2012) 0.96
Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal (2006) 0.95
Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis (2014) 0.94
Vaccine-derived polioviruses detected worldwide, July 2009 − March 2011. Wkly Epidemiol Rec (2011) 0.93
Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine (2015) 0.93
Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) (1971) 0.92
Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine (2012) 0.89
Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg Infect Dis (2010) 0.89
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines (2013) 0.89
An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Immunol Res (2014) 0.82
Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clin Immunol (2004) 0.81
Pediatric patients with common variable immunodeficiency: long-term follow-up. J Investig Allergol Clin Immunol (2012) 0.81
Health policy for common variable immunodeficiency: burden of the disease. J Investig Allergol Clin Immunol (2011) 0.80
Community-acquired poliovirus infection in children with primary immunodeficiencies in Tunisia. J Clin Microbiol (2003) 0.79
Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention. PLoS One (2013) 0.79
Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol (2014) 0.79
Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J Virol (2013) 0.77
Isolation of poliovirus shedding following vaccination in children with antibody deficiency disorders. J Infect Dev Ctries (2012) 0.76
Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis (2015) 1.03
An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis (2015) 0.96
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis (2015) 0.93
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis (2015) 0.84
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis (2016) 0.82
Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis (2016) 0.82